Cabozantinib: A Review in Advanced Renal Cell Carcinoma.

Abstract

The multiple tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx™) is approved in the USA for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy. In the EU, cabozantinib is indicated for the treatment of advanced RCC in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. In adults with advanced or metastatic clear-cell RCC who had previously received VEGF receptor (VEGFR) TKIs, progression-free survival (PFS) and overall survival (OS) were significantly prolonged in patients who received oral cabozantinib versus oral everolimus in the pivotal METEOR trial. Objective response was achieved in a significantly higher proportion of patients receiving cabozantinib than those receiving everolimus. Cabozantinib had a manageable adverse events profile in patients with advanced RCC. Thus, cabozantinib is an important new option for use in patients with advanced RCC who have previously received antiangiogenic therapy.

• Authors: Zaina T Al-Salama, Gillian M Keating
• Journal: Drugs (Drugs) Vol. 76 Issue 18 Pg. 1771-1778 (Dec 2016) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 27909994 (Publication Type: Journal Article, Review)

Chemical References

• Anilides
• Antineoplastic Agents
• Protein Kinase Inhibitors
• Pyridines
• cabozantinib
• Everolimus

Topics

• Anilides (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Renal Cell (drug therapy)
• Clinical Trials, Phase III as Topic
• Disease-Free Survival
• Everolimus (therapeutic use)
• Humans
• Kidney Neoplasms (drug therapy)
• Protein Kinase Inhibitors (therapeutic use)
• Pyridines (therapeutic use)